Robustness of the Centiloid scale to target and reference regions calculated with a commercial software using [ ¹⁸ F]flutemetamol PET images

Abstract

Background: Quantification of amyloid‐PET using the Centiloid (CL) scale has been increasingly used in clinical trials of AD modifying therapies and is set to play a role in clinical decision‐making.